Altimmune (Nasdaq:ALT) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ALT Stoklara Genel Bakış

Klinik aşamada bir biyofarmasötik şirketi olan Altimmune, Inc. obezite ve karaciğer hastalıkları için tedavi geliştirmeye odaklanmaktadır.

Şirket hakkında

ALT temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 71.47% oranında artması öngörülüyor

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $409K )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

Son 3 ayda dalgalı hisse senedi fiyatı

Altimmune, Inc. Rakipler

Frequency Therapeutics

NasdaqCM:FREQ

US$547.3m

Mereo BioPharma Group

NasdaqCM:MREO

US$675.9m

uniQure

NasdaqGS:QURE

US$275.1m

Sage Therapeutics

NasdaqGM:SAGE

US$405.4m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Altimmune
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$6.23
52 Haftanın En Yüksek Seviyesi	US$14.84
52 Haftanın En Düşük Seviyesi	US$2.09
Beta	0.064
11 Aylık Değişim	0.48%
3 Aylık Değişim	-9.58%
1 Yıllık Değişim	147.22%
33 Yıllık Değişim	-48.81%
5 Yıllık Değişim	217.92%
Halka arzdan bu yana değişim	-97.37%

Son Haberler & Güncellemeler

Recent updates

Consider Buying Potential Takeover Target Altimmune

Oct 02

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

Sep 21

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Sep 12

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Aug 27

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Jun 24

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

May 27

Buy Altimmune's Potential Market Disruption With Pemvidutide

Apr 12

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Mar 27

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Feb 27

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Feb 12

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Feb 10

Thoroughly Derisked, Altimmune Is Now A Great Buy

Jan 10

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

Oct 11

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Jun 27

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

Feb 12

We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Oct 27

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Sep 15

Reassessing Altimmune

Sep 07

Altimmune sets new 52-week high on rising volume

Aug 31

Altimmune Q2 2022 Earnings Preview

Aug 10

Altimmune: Several Catalysts In 2 Large Market Indications This Year

Jun 29

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Jun 27

Altimmune's New Avatar As A Liver Disease Player

Apr 07

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Feb 01

Altimmune: Changing Focus To Pemvidutide In 2022

Jan 03

Altimmune: Changing The Thesis

Oct 16

Here's Why Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Is The Least Of Shareholders Concerns

Sep 17

Hissedar Getirileri

	ALT	US Biotechs	US Pazar
7D	-3.7%	-0.5%	0.4%
1Y	147.2%	18.3%	32.6%

Getiri vs. Endüstri: ALT geçen yıl % 22.1 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: ALT geçen yıl % 34.1 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is ALT's price volatile compared to industry and market?
ALT volatility
ALT Average Weekly Movement	11.0%
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ALT hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: ALT 'nin haftalık oynaklığı ( 11% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1997	59	Vipin Garg	altimmune.com

Klinik aşamada bir biyofarmasötik şirketi olan Altimmune, Inc. obezite ve karaciğer hastalıkları için tedaviler geliştirmeye odaklanmaktadır. Şirketin öncü ürün adayı olan pemvidutide, obezite ve metabolik disfonksiyonla ilişkili steatohepatit tedavisi için Faz 2 denemesinde olan bir GLP-1 / glukagon çift reseptör agonistidir. Ayrıca, hepatit B virüsü ile kronik olarak enfekte olmuş hastalar için Faz 2 klinik çalışmasında olan immünoterapötik bir ürün adayı olan HepTcell'i geliştirmektedir.

Altimmune, Inc. Temel Bilgiler Özeti

Altimmune'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ALT temel i̇stati̇sti̇kler
Piyasa değeri	US$442.77m
Kazançlar(TTM)	-US$101.35m
Gelir(TTM)	US$409.00k

1,083x

P/S Oranı

-4.4x

F/K Oranı

ALT aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ALT gelir tablosu (TTM)
Gelir	US$409.00k
Gelir Maliyeti	US$77.94m
Brüt Kâr	-US$77.53m
Diğer Giderler	US$23.82m
Kazançlar	-US$101.35m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.43
Brüt Marj	-18,955.99%
Net Kâr Marjı	-24,778.97%
Borç/Özkaynak Oranı	0%

ALT uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ALT Stoklara Genel Bakış

Ödüller

Risk Analizi

Altimmune, Inc. Rakipler

NasdaqCM:FREQ

US$547.3m

NasdaqCM:MREO

US$675.9m

NasdaqGS:QURE

US$275.1m

NasdaqGM:SAGE

US$405.4m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Consider Buying Potential Takeover Target Altimmune

Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (Mash)

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Altimmune, Inc., Annual General Meeting, Sep 26, 2024

Recent updates

Consider Buying Potential Takeover Target Altimmune

Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (Mash)

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Altimmune, Inc., Annual General Meeting, Sep 26, 2024

Altimmune, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Altimmune, Inc. Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association’s 84th Scientific Sessions

Altimmune, Inc. Presents Data at EASL International Liver Congress™? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)

Pomerantz LLP Announces Filing of Class Action Against Altimmune, Inc. and Certain Officers

Altimmune, Inc. to Report Q1, 2024 Results on May 09, 2024

Buy Altimmune's Potential Market Disruption With Pemvidutide

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023

Altimmune, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

President exercised options and sold US$115k worth of stock

Thoroughly Derisked, Altimmune Is Now A Great Buy

Price target increased by 11% to US$21.29

Altimmune, Inc. Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Altimmune, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Altimmune, Inc. Grants Fast Track Designation by FDA for Pemvidutide for the Treatment of Non Alcoholic Steatohepatitis (Nash)

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates decrease by 29%

Altimmune, Inc., Annual General Meeting, Sep 28, 2023

Consensus revenue estimates increase by 11%

Price target decreased by 21% to US$19.38

Altimmune, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Altimmune, Inc. Announces Initiation of Phase 2b Impact Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Al Alcoholic Steatohepatitis

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Price target decreased by 11% to US$26.25

Altimmune, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased by 11% to US$26.25

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

President exercised options and sold US$106k worth of stock

Altimmune, Inc. Appoints Raymond Jordt as Chief Business Officer

Independent Director exercised options and sold US$248k worth of stock

Altimmune, Inc. Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Altimmune, Inc. to Report Q3, 2022 Results on Nov 10, 2022

We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Altimmune, Inc. Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

Altimmune, Inc. Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Reassessing Altimmune